CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS(2022)
Abstract
Bladder cancer (BC) is one of the most common malignant tumors of the urinary system worldwide. To date, immune checkpoint inhibitors (including PD-1/PD-L1) have been applied to treat patients with bladder cancer in the clinic and achieved the promising outcome. Further improvement of the anticancer efficiency of these immune therapies is crucial for bladder cancer. Our previous RNA-seq data on CBX7 (GSE185630) suggested that CBX7 might repress PD-L1 expression and PD- 1 checkpoint pathway in cancer. In this study, we revealed that CBX7 downregulated the expression of POU2F2 that indirectly repressed the PD-L1 in BC cells. Depletion of CBX7 resulted in resistance to PD-1 blockade in bladder cancer. Collectively, our results suggested that the CBX7/POU2F2/PD- L1 axis plays an important role in determining the antitumor effect of PD-1 blockade in bladder cancer. (C) 2022 Elsevier Inc. All rights reserved.
MoreTranslated text
Key words
Bladder cancer,CBX7,POU2F2,PD-L1
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined